ASTEROID TRIAL ROSUVASTATIN PDF

When we see less plaque after a treatment period, all the limitations aside, we believe it will be confirmed with a morbidity and mortality benefit. All patients were treated with rosuvastatin Crestor, AstraZeneca at 40 mg daily. Researchers assessed coronary atheroma burden by IVUS at 24 months. Of the patients treated with rosuvastatin, withdrew or did not have a viable IVUS reading, which left patients available for evaluation.

Author:Mikall Vot
Country:Bulgaria
Language:English (Spanish)
Genre:Finance
Published (Last):10 June 2015
Pages:27
PDF File Size:6.86 Mb
ePub File Size:13.87 Mb
ISBN:869-5-69098-781-1
Downloads:26645
Price:Free* [*Free Regsitration Required]
Uploader:Kazim



Context: Prior intravascular ultrasound IVUS trials have demonstrated slowing or halting of atherosclerosis progression with statin therapy but have not shown convincing evidence of regression using percent atheroma volume PAV , the most rigorous IVUS measure of disease progression and regression. Objective: To assess whether very intensive statin therapy could regress coronary atherosclerosis as determined by IVUS imaging.

A motorized IVUS pullback was used to assess coronary atheroma burden at baseline and after 24 months of treatment. Each pair of baseline and follow-up IVUS assessments was analyzed in a blinded fashion. Patients: Between November and October , patients had a baseline IVUS examination and received at least 1 dose of study drug. After 24 months, patients had evaluable serial IVUS examinations. Main outcome measures: Two primary efficacy parameters were prespecified: the change in PAV and the change in nominal atheroma volume in the mm subsegment with the greatest disease severity at baseline.

A secondary efficacy variable, change in normalized total atheroma volume for the entire artery, was also prespecified. The mean SD change in atheroma volume in the most diseased mm subsegment was Change in total atheroma volume showed a 6. Adverse events were infrequent and similar to other statin trials. Treatment to LDL-C levels below currently accepted guidelines, when accompanied by significant HDL-C increases, can regress atherosclerosis in coronary disease patients.

Further studies are needed to determine the effect of the observed changes on clinical outcome. Trial registration: ClinicalTrials. This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. Search: Search. Advanced Clipboard. Create file Cancel. Email citation To:. Format: Summary Summary text Abstract Abstract text.

Send email Cancel. Add to Collections Create a new collection Add to an existing collection. Name your collection: Name must be less than characters. Choose a collection: Unable to load your collection due to an error Please try again. Add Cancel. Add to My Bibliography My Bibliography.

Unable to load your delegates due to an error Please try again. Your saved search Name of saved search:. Search terms:. Test search terms. Would you like email updates of new search results? Email: change. Frequency: Monthly Weekly Daily. Which day? Send at most: 1 item 5 items 10 items 20 items 50 items items items.

Send even when there aren't any new results. Optional text in email:. Save Cancel. Create a file for external citation management software Create file Cancel.

Full-text links Cite Favorites. Abstract Context: Prior intravascular ultrasound IVUS trials have demonstrated slowing or halting of atherosclerosis progression with statin therapy but have not shown convincing evidence of regression using percent atheroma volume PAV , the most rigorous IVUS measure of disease progression and regression.

Comment in Can a potent statin actually regress coronary atherosclerosis? Blumenthal RS, et al. Epub Mar PMID: No abstract available.

Can intensive statin therapy cause regression of coronary atherosclerosis? Newby DE. Nat Clin Pract Cardiovasc Med. High-dose statins and atherosclerosis regression. Rozenman Y. Port SC. Effect of very high intensity statin therapy on regression of coronary atherosclerosis. Clearfield M. Curr Atheroscler Rep. Scheen AJ. Rev Med Liege. PMID: French. Factors underlying regression of coronary atheroma with potent statin therapy.

Puri R, et al. Eur Heart J. Epub May 3. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN.

Eur Heart J Cardiovasc Imaging. Epub Jan Coronary atherosclerosis can regress with very intensive statin therapy. Sipahi I, et al. Cleve Clin J Med. PMID: Review. Effect of statin therapy on the progression of coronary atherosclerosis. Tian J, et al. BMC Cardiovasc Disord. Show more similar articles See all similar articles. Cited by articles Effects of nanoparticle-mediated delivery of pitavastatin on atherosclerotic plaques in ApoE-knockout mice and THPderived macrophages.

Sun Y, et al. Exp Ther Med. Epub Apr 1. Atorvastatin-loaded solid lipid nanoparticles as eye drops: proposed treatment option for age-related macular degeneration AMD. Yadav M, et al. Drug Deliv Transl Res.

Online ahead of print. Kim KJ, et al. J Clin Med. Development of rosuvastatin flexible lipid-based nanoparticles: promising nanocarriers for improving intestinal cells cytotoxicity. Ahmed TA. BMC Pharmacol Toxicol. Atherosclerosis: Making a U Turn. Goldberg IJ, et al. Annu Rev Med. PMID: Show more "Cited by" articles See all "Cited by" articles. Publication types Clinical Trial Actions.

Multicenter Study Actions. MeSH terms Aged Actions. Cholesterol, HDL Actions. Cholesterol, LDL Actions. Female Actions. Humans Actions.

RANDEL HELMS GOSPEL FICTIONS PDF

ASTEROID: IVUS shows regression with rosuvastatin

Context: Prior intravascular ultrasound IVUS trials have demonstrated slowing or halting of atherosclerosis progression with statin therapy but have not shown convincing evidence of regression using percent atheroma volume PAV , the most rigorous IVUS measure of disease progression and regression. Objective: To assess whether very intensive statin therapy could regress coronary atherosclerosis as determined by IVUS imaging. A motorized IVUS pullback was used to assess coronary atheroma burden at baseline and after 24 months of treatment. Each pair of baseline and follow-up IVUS assessments was analyzed in a blinded fashion.

BOOK OF THE ASTRONOMICAN PDF

ASTEROID trial

Rosuvastatin therapy lowered low-density lipoprotein cholesterol to This was associated with a significant reduction in all IVUS measures of atheroma burden. These results suggest that intensive modification of lipid levels with high-dose statin therapy can promote atheroma regression. Further studies will be required to determine whether this benefit is associated with a reduction in clinical events. This site needs JavaScript to work properly.

LAUBER HAGER PDF

The ASTEROID Trial: Coronary Plaque Regression With High-Dose Statin Therapy

Study record managers: refer to the Data Element Definitions if submitting registration or results information. To evaluate the change in lipid and lipoprotein levels as assessed by percentage change from baseline. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. Use of lipid-lowering medication for more than 3 months within the previous 12 months.

Related Articles